Practical Applications of Russian DPP4 Inhibitor Gosogliptin in “Palitra” Large-Scale Observational Study
BACKGROUND: To date, the results of Metformin, Gosogliptin and combination thereof have not been studied on a large patient population with type 2 diabetes mellitus (DM2), including comorbid patients, in real clinical settings in the Russian Federation.AIM: The aim is to evaluate the efficacy, safet...
Saved in:
| Main Authors: | M. V. Shestakova, E. V. Biryukova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2024-09-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13193 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
by: Karina Oganesovna Galstyan, et al.
Published: (2016-01-01) -
Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-12-01) -
Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study
by: Natalya Vladislavovna Zaytseva, et al.
Published: (2015-06-01) -
Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01) -
Relationships between serum lipid profile and HbA1c levels in patients with diabetes
by: Habibeh Sadat Mosavi, et al.
Published: (2024-07-01)